恶性葡萄胎患者化疗前后血清TNF—α、EGF检测的临床意义

目的：探讨了恶性葡萄胎化疗前后血清TNF-α和EGF水平的变化及临床意义。方法：应用放射免疫分析对32例恶性葡萄胎患者进行了血清TNF-α和EGF水平的检测，并与35名正常健康人作比较。结果：恶性葡萄胎患者在化疗前血清TNF-α和EGF水平均非常显著地高于正常人组（P〈0．01），经化疗后6个月，与正常人组比较仍有显著性差异（P〈0．05）。结论：恶性葡萄胎患者的发生和发展与血清TNF-α和EGF水平的变化密切相关。

Clinical Significance of Measurement of Changes of Serum TNF-α and EGF Levels After Chemotherapy in Patients with Malignant Hydatidiform Mole

Objective To study the clinical significance of changes of serum TNF - α and EGF levels after chemotherapy in patients with malignant hydatidiform mole. Methods Serum TNF - α, EGF levels （ with RIA） were measured both before and after chemotherapy in 32 patients with malignant hydatidiform mole as well as in 35 controls. Results Before chemotherapy, serum TNF - α and EGF levels were significantly higher in the patients than those in controls （ P 〈 0.01 ）. Six months after chemotherapy, serum TNF - α and EGF levels, though dropped markedly, remained significantly higher than those in controls （ P 〈 0.05 ）. Conclusion Development of malignant hydatidiform mole in patients was closely related to the serum TNF - α and EGF levels.